Sleeve Gastrectomy enhances glucose utilization and remodels adipose tissue independent of weight loss

David A. Harris¹, Amir Mina², Dimitrije Cabarkapa², Keyvan Heshmati¹, Renuka Subramaniam¹, Alexander S. Banks², Ali Tavakkoli¹, Eric G. Sheu¹

1. Laboratory for Surgical and Metabolic Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
2. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Corresponding author: Eric G. Sheu MD, PhD, esheu@bwh.harvard.edu

Declaration of Interest: The authors have declared that no conflict of interest exists

Funding Sources:

This work was conducted with the support of two funding sources from the senior author and one from the first author. First, was an appointed KL2 award from Harvard Catalyst. The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award KL2 TR002542). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health. Second, funding was obtained through a Pilot Grant from the Boston Area Diabetes and Endocrinology Research Center (BADERC). Finally, a two year, competitive research scholarship from the American College of Surgeons.

ABSTRACT

Objective: Sleeve gastrectomy (SG) induces weight-loss independent improvements in glucose homeostasis by unknown mechanisms. We sought to identify the metabolic adaptations responsible for these improvements.

Methods: Non-obese C57Bl6/J mice on standard chow underwent SG or sham surgery. Functional testing and indirect calorimetry were used to capture metabolic phenotypes. Tissue-specific glucose uptake was assessed by 18-FDG PET/CT and RNA sequencing was used for gene expression analysis.

Results: In this model, SG induced durable improvements in glucose tolerance despite not causing lasting changes in weight, fat/lean mass, or food intake. Indirect calorimetry revealed post-SG animals had respiratory exchange ratios (RER) nearing 1.0 on average and had daily RER excursions above 1.0, indicating preferential glucose utilization and increased energy demand, respectively. Sham operated mice demonstrate normal RER feeding/fasting excursions. PET/CT showed increased avidity within white adipose depots. Finally, SG led to an upregulation in the transcriptional pathways involved in energy metabolism, adipocyte maturation, and adaptive and innate immune cell chemotaxis and differentiation within the visceral adipose tissue.

Conclusions: SG induces a rapid, weight-loss independent shift towards glucose utilization and transcriptional remodeling of metabolic and immune pathways in visceral adipose tissue.

KEYWORDS: Sleeve Gastrectomy, Diabetes, Glucose utilization, Respiratory exchange ratio, indirect calorimetry

ABBREVIATIONS: SG (Sleeve Gastrectomy), POD (post-operative Day), GLP-1 (glucagon like peptide 1), OGTT (oral glucose tolerance test), ITT (insulin tolerance test), PET/CT (positron emission tomography-computed tomography), CLAMS (comprehensive lab animal monitoring systems), RER (respiratory exchange ratio), EE (energy expenditure), DNL (de novo lipogenesis), VAT (visceral adipose tissue), T2D (Type 2 Diabetes), FXR (farnesoid X Receptor), PPAR γ (peroxisome proliferator-activated receptor gamma), FOXO1 (forkhead box protein O1), SMRT (silencing mediator of retinoid and thyroid hormone receptors), NCOR (nuclear receptor co-repressor), MECOM (MDS1 and EVI1 Complex Locus), SUZ12 (Polycomb Repressive Complex 2 Subunit), E2A (E2A immunoglobulin enhancer-binding factor E12/E47), MTF2 (Metal Response Element Binding Transcription Factor 2), GATA3 (gata binding protein 3)

1. INTRODUCTION

Bariatric surgery in the form of sleeve gastrectomy (SG) has become the most performed metabolic surgery in the United States. SG leads to rapid and durable improvements in type 2 diabetes (T2D) and this effect often precedes weight loss. [1-4] In fact, nearly 40% of patients with diabetes who undergo SG leave the hospital without needing anti-diabetic medications. [5] Interestingly, there has also been increasing evidence that non-obese, metabolically unhealthy patients can have remission of T2D following surgical intervention. [6] Thus, clinically, there are weight-loss independent, SG-induced adaptations that lead to improved glucose homeostasis.

Multiple pre-clinical and clinical studies aimed at identifying the molecular basis for post-SG T2D remission show that surgery leads to complex changes in incretin hormone and bile acid production, changes in gut microbial composition, intestinal cellular adaptation, and immune modulation. [7-9] However, multiple authors have revealed that while these processes play a role in post-surgical T2D remission, they are not sufficient, in-and-of-themselves, to cause remission. [10] [11-13]

Furthermore, there has been little directed effort to identifying which of these changes, if any, are responsible for the early, weight-loss independent T2D improvement seen clinically. Investigators have tried to address this by using sham pair-feeding and have shown that SG can lead to adipose adaptive immune cell changes, improved muscle and hepatic insulin sensitivity, and reduced hepatic steatosis in the absence of significant weight loss. [9,14,15] However, one major limitation to these studies is that they are derived in obese models where animals lose weight following surgery and are maintained on non-physiologic, high-fat diets indefinitely. This makes it increasingly difficult to define the SG-specific, weight-loss specific, and diet-specific changes that are occurring after SG. Thus, currently the weight and diet independent metabolic adaptations and target tissue of SG remain poorly defined.

Here, we describe a novel model of SG in non-obese mice and show that SG leads to weight independent changes in glucose tolerance. This post-SG phenotype is defined by a global metabolic shift towards increased glucose utilization and appears to lead to, or be the result of, visceral adipose tissue (VAT) immunologic remodeling, glucose sequestration, and glucose use.

2. MATERIALS AND METHODS

2.1 Animals. 11-week-old, male, C57Bl/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME). They were housed in a climate-controlled environment with a 12-hour light/dark cycle and reared on a normal rodent chow (5% calories from fat; Pico5053, Lab diet, St. Louis, MO). They acclimated for 1 week prior to undergoing any procedure. Figure 1 outlines the overall experimental design. All procedures were approved by the Institutional Animal Care and Use Committee and animals were cared for according to guidelines set forth by the American Association for Laboratory Animal Science.

2.2 Sleeve gastrectomy (SG) and sham procedures. Mice were weight-matched into two groups and either underwent SG or Sham operation. Under isoflurane anesthesia, SG and Sham procedures were performed via a small midline laparotomy. In SG, the stomach was dissected free from its surrounding attachments, the short gastric vessels between the stomach and spleen were divided, and a tubular stomach was created by removing 80% and 100% of the glandular and non-glandular stomach, respectively. Sham operation consisted a similar gastric dissection, short gastric vessel ligation, and manipulation of the stomach along the staple line equivalent. Short gastric vessel ligation was chosen as part of our control as ligation of these vessels effect portal venous flow. Signaling through the portal vein has been shown to be important in the body's ability to sense and respond to glucose. [16,17] Mice were then individually housed thereafter to allow for monitoring of food intake, weight, and behavior. After surgery, SG and Sham mice were maintained on Recovery Gel Diet (Clear H₂O, Westbrook, ME) for 6 days and then restarted on normal chow.

2.3 Functional glucose testing. Oral glucose tolerance testing (OGTT) was performed on post-operative week 2 and 4 and insulin tolerance testing (ITT) was performed on post-operative week 2. Animals underwent a 4 hour fast (8 am to noon). During OGTT, mice received 2mg/g of oral D-Glucose (Sigma-Aldrich, St. Louis, MO) and serum glucose levels were measured from the tail vein at 15, 30, 60, and 120 min with a OneTouch Glucometer (Life technologies, San Diego, CA). ITT was performed by intraperitoneal instillation of 0.6U/kg of regular human insulin (Eli Lilly and Company, Indianapolis, IN) and measurement of serum glucose levels at 15, 30, and 60 min. Baseline glucose was measured for each animal prior to medication administration. An ELISA assay was used to quantify the concentration of total glucagon like peptide-1 (GLP-1) in circulation 15 minutes following glucose gavage as above (Crystal Chem, Cat81508, Elk Grove Village, IL). Each functional assay represents a separate animal experiment.

2.4 Body composition analysis and Comprehensive Animal Monitoring Systems (CLAMS). A separate group of SG and Sham mice were placed into CLAMS systems from post-operative day 7 to 14 and then again on post-operative day 27 to 34. Body composition of each mouse was determined by MRI spectroscopy. Mice were then placed into individual temperature-controlled cages within the CLAMS system, which was maintained with a normal 12-hour light/dark cycle at 22°C. Mice had access to food and water ad libitum. Individual mouse CO₂ expenditure, O₂ consumption, food consumption, and locomotor and ambulatory were collected over the week. The first 24 hours of each experiment was discarded to account for mouse acclimation. Energy expenditure and the respiratory exchange ratio were calculated. CLAMS data was analyzed using the open source program CalR as previously described [18]. Experimentation from post-operative day 7 to 14 was completed in triplicate and the data was pooled for analysis (Sham n =14; SG n= 15). A single longitudinal study was completed for CLAMS caging (post-operative day 27 to 34, sham n = 5, SG n = 4).

2.5 PET/CT imaging with 18-Fluoro-deoxyglucose. Two separate experiments were completed to explore glucose handling in SG mice. Two weeks following SG (n=2) or sham (n=2) operations, mice underwent PET/CT imaging with orally delivered 18-FDG. Each mouse was

administered 200 μ l of 18-FDG such that there was equivalency in the dose of molar glucose given. Under isoflurane anesthesia, PET/CT experimentation was completed over multiple days so that the activity of delivered 18-FDG varied between 116 and 300 μ CI. Using PMOD software (PMOD technologies LLC, Zurich, Switzerland) time activity curves were created over a 60 minutes and PET imaging was overlaid onto captured CT images. In a second replicate experiment SG (n=2) and sham mice (n=3) were treated similarly. Mice were euthanized and whole blood and organs were placed into a well counter to assess for overall activity. Data from well counting are pooled between the two experiments (SG n=4 and sham n=5). Comparisons between organ SUV was completed in GraphPad Prism.

2.6 RNAseq of visceral fat. Two weeks following SG (n=5) or sham (n=5) operations, mice were euthanized and visceral fat (intra-abdominal, epididymal fat pad) was collected. [19] Total RNA was extracted according to the manufacturer's instructions (Qiagen, RNeasy Lipid Tissue Mini). RNA quality was ensured using an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). Libraries were prepared using Roche Kapa RiboErase rRNA depletion stranded totalRNA Hyper Prep sample preparation kits from 100ng of purified total RNA according to the manufacturer's protocol. The finished dsDNA libraries were quantified by Qubit fluorometer, Agilent TapeStation 2200, and RT-qPCR using the Roche Kapa library quantification kit according to manufacturer's protocols. Uniquely indexed libraries were pooled in equimolar ratios and sequenced on an Illumina NextSeq500 with paired-end 75bp reads by the Dana-Farber Cancer Institute Molecular Biology Core Facilities. Sequenced reads were aligned to the UCSC mm9 reference genome assembly and gene counts were quantified using STAR (v2.5.1b). [20] Differential gene expression testing was performed by DESeq2 (v1.10.1) and normalized read counts (FPKM) were calculated using cufflinks (v2.2.1). [21,22] RNAseq analysis was performed using the VIPER snakemake pipeline. [23]

The EnrichR platform was used to assess gene expression ontology. [24,25] Functional enrichment with WikiPathways 2019 Mouse and ChEA2016 Transcription pathway analysis are reported.

2.7 Statistics. GraphPad Prism 8 (San Diego, Ca), CalR statistical software [18], and the Enrichr platform (<http://amp.pharm.mssm.edu/Enrichr/>) were used for data analysis. Student's t-tests were used for continuous variables. General linear modeling was used where appropriate with a lean mass covariate. Statistical significance is denoted in figures and text. For RNA-seq, gene ontology and transcriptional pathways, adjusted p-values<0.05 are listed in order of Enrichr combined score, which is the product of the log of the Fischer's exact p-value and the z-score (deviation from expected rank).

3 RESULTS

3.1 Weight-loss independent improvements in glucose metabolism following sleeve gastrectomy

To investigate the weight-loss independent, anti-diabetic effects of SG, we developed a novel model of SG in 11-week old C57Bl/6J mice reared on standard chow. After a 1-week acclimation period, mice underwent either SG or sham operation. While there was an initial

difference in weight loss in SG mice as compared to sham control animals, by post-operative day (POD) 7, mice from both groups showed identical weights (Figure 2A). Mice were restarted on solid chow on POD 6. By POD 7, overall caloric intake as measured by daily food weight was not different between groups (Figure 2B). Further, MRI body composition analysis revealed that SG mice had reduced fat and lean mass during the first operative week, but by POD 14, all mice had identical body composition (Figure 2C). Thus, this model is well suited to study the weight-loss independent effects of SG.

Despite equivalency in weight, caloric intake, and body composition by post-operative day 14, SG mice displayed distinctly different glucose handling compared to their Sham counterparts. Oral glucose tolerance testing was performed in the second post-operative week. While SG and Sham animals had no difference in fasting or maximal glucose peak, glucose levels in SG animals rapidly cleared, with serum levels dropping nearly 200 mg/dL to baseline levels in the 15 min following maximal glycemia. This change was still evident at 4 weeks (Figure 3 A and B). Additionally, SG animals had a more rapid decline in serum glucose levels during ITT 2 weeks post-surgery; although, there was no difference in AUC between groups (AUC Sham vs. SG, 5527 ± 851 vs 3792 ± 598 , $p = 0.127$). Of note, during this testing, two SG animals and one Sham had to be rescued from hypoglycemia at 60 minutes. In keeping with the known post-SG physiology in humans, SG mice had increased serum GLP-1 levels in response to oral glucose stimulation at 15 minutes (Figure 3d). These data demonstrate improved glucose homeostasis in mice following SG, independent of differences in body composition.

3.2 Indirect calorimetry reveals increased carbohydrate utilization in SG mice

To gain a better understanding of the metabolic changes underlying the observed weight-loss independent improvement in glucose handling by SG mice, we next utilized indirect calorimetry via Comprehensive Lab Animal Monitoring Systems (CLAMS) to capture the energy balance of these animals. SG and Sham mice were placed into CLAMS cages from POD 7 to 14. The most notable change occurred in the respiratory exchange ratio (RER; Table A1). As typical of mice fed a standard rodent chow, the RER of Sham animals ranged from 0.85 to 1.0 during light and dark photoperiods corresponding, roughly, to periods of fasting and feeding, respectively. In contrast, SG mice had a strikingly high RER ranging from an average of 0.9 to an average peak near 1.05. RER values greater than 1.0 suggest either increased glucose utilization or a process such as de-novo lipogenesis (Figure A and B). [26] Importantly, there was equivalency in the total food consumed in a 24-hour period and ambulatory activity (Table A2). During the first post-operative week, SG mice showed a reduction in the EE across all times of day (Figure 4C, Figure A3). The effect on EE reduction is consistent with effects seen in food restriction experiments for weight loss in rodents and humans. [27,28] However, the effect on RER is novel.

After two additional weeks of normal housing and daily monitoring, mice were again placed into CLAMS cages (POD 27 to 34). At this point, SG and Sham mice had similar total (26.3 ± 0.31 vs. 25.4 ± 0.33 , $p=0.58$), fat (4.1 ± 0.3 vs. 4.0 ± 0.1 , $p=0.70$), and lean masses (22.0 ± 0.9 vs 21.6 ± 0.3 , $p=0.53$). During this week, SG and Sham mice had the same caloric intake, the

same overall energy expenditure, and same activity level. However, the elevation in the RER after SG persisted (Table A4) indicating that changes in RER are durable and important in the underlying physiology of SG.

3.3 Positron-emission tomography with oral 18-FDG reveals a tissue-glucose sink

We next sought to identify the tissue responsible for rapid systemic glucose utilization during OGTT and for the RER changes seen in SG mice. As shown in Figure 5a, oral delivery of 18-FDG to SG mice led to rapid distal delivery of the glucose analog when compared to Sham animals. Time activity curves generated from PET/CT imaging revealed that the glucose analog remained stagnant in the stomach and very proximal small bowel in Sham animals, while in SG animals there was rapid gastric clearance and delivery to the distal small bowel within 60 minutes (Figure 5B).

Quantification of 18-FDG avidity by well counter at 90 minutes showed that most tissues had equivalency in total glucose uptake (Table A5). There were no statistically significant differences in bowel segment avidity. However, there was a significant increase in the avidity of cecal stool in SG animals suggesting that there is increased luminal transit, as opposed to an increased enterocyte uptake and capture of 18-FDG. However, in SG animals, there was increased 18-FDG present across all fat depots tested – mesenteric, epididymal, and subcutaneous – suggesting that metabolic changes within these fat depots could explain the post-SG physiology.

3.4 RNA sequencing reveals gene level changes in visceral fat immunity and metabolism

Metabolic dysregulation and inflammation of the visceral adipose tissue (VAT) are known, potent contributors to the pathogenesis of metabolic syndrome. Thus, changes in gene expression and transcriptional programming in this depot may underlie the post-SG improvements. Given the increase in 18-FDG in the VAT of SG mice and its known importance to metabolic regulation, we utilized RNA sequencing to better understand the gene expression profile and transcriptional networking of this depot in SG.

Table 1 outlines significant gene-level changes following SG. There was a large shift in the immunologic gene expression profile of post-SG VAT with increased expression of CXCL13 and CCL8, CISH, and IgJ corresponding to up-regulation of B and T cell chemotaxis, regulation of T cell activation, and immunoglobulin cross linking, respectively. We also observed changes in the VAT metabolic gene profile with an upregulation of EHHADH – a peroxisomal enzyme responsible for beta oxidation of fatty acids – and related processes of fatty acid beta-oxidation, peroxisome function, and amino acid metabolism. In keeping with the published human data showing decreased systemic and organ-specific leptin levels following sleeve gastrectomy, there was a reduction in the leptin (LEP) expression within the VAT of SG animals [29-31]. There was also a reduction in oxytocin receptor signaling, which partially controls adipogenesis and fat accumulation in fat-tissue depots [32].

Next, pathway analysis was completed with the use of WikiPathways 2019. Again, there was an upregulation of immune-centric pathways including phagocytosis, IL-2, IL-3, IL-5, chemokine signaling, and TYRO protein tyrosine kinase binding protein signaling. The latter is associated with immune cell maturation and activation (Table 2). There were no pathways that were down regulated.

Finally, transcription factor binding sites upstream of these target gene sets were identified via ChEA2016 pathway analysis (Figure 6). The gene expression profile in SG VAT mapped to traditional master-regulators involved in lipid and glucose homeostasis – peroxisome proliferator-activated receptor gamma (PPAR γ) and forkhead box protein O1 (FOXO1) – responsible for diverse processes including glucose metabolism and adipocyte cell fate. There was contribution from silencing mediator of retinoid and thyroid hormone receptors (SMRT) and nuclear receptor co-repressor (NCOR), which through subdomains, effect PPAR γ signaling and modulate the immune response by transrepression of co-activators of NF-kB, IRFs and LPS targets. [33-36] Finally, there was expression mapping to other transcription factors such as Interferon-regulatory factor 8 (IRF8), MDS1 and EVI1 Complex Locus (MECOM), Polycomb Repressive Complex 2 Subunit (SUZ12), and E2A immunoglobulin enhancer-binding factor E12/E47 (E2A), which have roles in determining immune cell fate, cell resource utilization, and/or other metabolic processes.

Transcriptional program analysis of downregulated pathways revealed a shared SUZ12 signature, suggesting that alternative expression of downstream products may be important to the global change in fat homeostasis and inflammation following SG. This is further supported by downregulation in the Metal Response Element Binding Transcription Factor 2 (MTF2), which guides SUZ12 to specific promoters. [37] Finally, there was a decrease in gata binding protein 3 (GATA3) which is classically associated with a TH2 immune response but is also prevalent in adipocyte precursors. GATA3 also suppresses PPAR γ , so its downregulation is in keeping with the observed increase PPAR γ expression identified in the VAT of SG mice. [38]

4 DISCUSSION

The immediate benefits of SG on glucose metabolism and insulin resistance has been documented in both human patients and mice. We have previously shown that within days of surgery, roughly 40 percent of human patients have durable improvement, or resolution, in their diabetes. [5] The mechanisms behind these early, rapid changes are unknown but are critical to understanding the benefits of surgery. Our study in mice suggests that SG leads to an increase in visceral fat glucose uptake and global glucose utilization, which either drives, or is the sequela of, immunologic remodeling. We postulate that these processes likely underlie immediate post-SG improvements in glucose handling.

To date, most murine studies of SG have utilized a diet-induced model of obesity (DIO) or a genetically obese model, combined with sham pair-feeding, in an attempt to recapitulate and study SG physiology. [9,11,14,15,39-41] While mice in these studies become obese and have hyperglycemia similar to the target patient population, investigations are limited by

differences in food intake via pair-feeding and/or differences in body weight between the surgical intervention and sham groups. Furthermore, in most experiments, pair feeding induces weight loss. Here, we show that the immediate, weight-loss independent effects of SG can be modeled in lean, wildtype, C57Bl/6J mice reared on standard rodent chow. In this model, SG and sham mice have similar food intake profiles. Thus, this model decouples the effects of surgery from changes in diet and body composition.

In our model, SG and sham animals showed equivalent weight, body composition, and daily food intake without pair feeding. Despite this, SG animals had improvements in glucose homeostasis, insulin resistance, and increased circulating GLP-1; all of which are hallmarks of post-SG physiology. [30] Specifically, when challenged with oral glucose, SG animals showed a dramatic reduction in systemic glucose levels 15 to 30 minutes post gavage with a corollary increase in serum GLP-1 expression at 15 minutes. This “glucose sink” phenomenon suggested increased tissue glucose uptake and utilization. In addition, this adds to the growing literature that SG, in the absence of weight loss, leads to changes in metabolic physiology. [9,14,15]

Indirect calorimetry corroborated these findings. The RER, or the ratio of CO₂ produced to O₂ consumed, is a function of the substrate of cellular respiration. When an animal is predominantly using carbohydrates as a fuel source, the RER approximates 1.0 as every molecule of O₂ consumed produces a single molecule of CO₂. When an animal uses fatty acids as a source of respiration, the RER approaches 0.7. During a typical 24-hour cycle, sham mice vacillated between 0.85 and 1.0 corresponding to fasting or feeding, respectively. However, SG animals had a durable increase in the RER which neared 1.0 during both night and dark cycles indicating preferential glucose utilization during both fasting and feeding. Thus, in SG mice there appears to be an early cellular adaptation to increased glucose allocation and utilization likely leading to long term improvements as shown by the continually elevated RERs in SG mice 4 weeks following surgery.

Interestingly, calorimetry also revealed that SG mice had daily RER excursions above 1.0 and nearing 1.1. This phenomenon has been described previously in maximally exercising individuals as a surrogate marker for attainment of the maximum VO₂ and in metabolically expensive processes, such as de novo lipogenesis (DNL), owing to its reliance on the pentose phosphate pathway to produce reducing equivalents. [42] [26,43] Studies of RER in humans and mice following SG are limited. Dereppe et al., have shown that human patients following bariatric surgery have an increase in the maximal RER attained (up to an average of 1.28) while exercising. [44] However, SG mice in the current study, do not show an increase in ambulatory activity to suggest exercise, or the equivalent, as the main driver of RER elevations.

PET-CT imaging showed increased 18-FDG uptake across all white adipose depots in SG compared to sham animals suggesting that these depots are, in part, responsible for the glucose sink phenomenon and the elevations in RER. Importantly, this change occurred in the absence of changes in overall, fat, and lean mass and thus appear surgery specific. In contrast to Saedi and colleagues who found that intravenously delivered 18-FDG was sequestered to the alimentary roux-limb of rats following Roux-en-Y gastric bypass, we found no difference in

bowel specific glucose uptake in SG animals. [45] These differences may be related to the route of 18-FDG administration. However, owing to the importance of incretin hormones in post-SG outcomes, we felt that orally administered glucose was more physiologically relevant. These differences highlight that while these two procedures may result in clinically and physiologically similar outcomes, they may differ in how those outcomes are achieved.

Based on these findings we explored VAT gene-level changes in SG mice. This revealed an upregulation in multiple metabolic processes that potentially indicate increased lipolysis, increased de novo lipogenesis, and modulated adipocyte cell fate. For example, upregulation in FOXO1 pathways and the gene EHHADH indicates increased lipolysis and beta oxidation of long chain fatty acids, respectively. [46,47] SG animals also had an upregulation in MECOM regulated pathways, which are associated with increased purine and pyrimidine metabolism, amino acid metabolism, pentose phosphate pathway reliance, and glycolysis. [48]. Elevations in PPAR γ , SMRT, and NCOR which all interact to control downstream adipocyte fate and function, glucose handling, insulin sensitivity, mitochondrial oxidative capacity, and thermogenesis, were also found. [43,49] [36,50] [33] [51-53]. Thus, as inferred from the calorimetry data, there is upregulation of transcriptional machinery capable of increasing energy production and glucose utilization within the VAT of SG mice.

Unexpectedly, SG mice had an upregulation in multiple immune processes within the VAT. Most of the isolated, gene-level changes occurred in pathways for myeloid and B cell chemotaxis and differentiation. Increased levels of CXCL13 and IgJ suggests B cell chemotaxis to SG VAT and increased immunoglobulin production and crosslinking. Upregulation of transcription factors outlined in Figure 6 are likely underlying these changes. [54] These again include NCOR and SMRT, which both coordinate to modulate the immune response through NF-kB, IRFs and LPS target genes and reduce the pro-inflammatory phenotype of macrophages. [34,35]. We also identified a robust signal in IRF8, which is associated with innate and adaptive immune response and adipocyte metabolic regulation [55] [56,57] and SUZ12, which has been shown to be a regulator of energy metabolism through modulation of brown fat thermogenesis. [58,59]

Taken as a whole, these data suggest that there is a complex interaction between the metabolic activity of the VAT and the local immune cell fraction in SG animals. However, given both the metabolic and immune gene profiling outlined above, it is unclear if local adipocyte function is driving immune changes or if there is immunologic remodeling leading to increase glucose sequestration and utilization. As outlined by Solinas and colleagues, adipocyte processes, like DNL, are capable of driving both local and global metabolic and immune function via PPAR signaling and effecting GLP-1 secretion, hepatic lipogenesis, insulin sensitivity, and the host gut barrier and immunity. [60] [43,61] Alternatively, it is plausible that local immune remodeling is driving metabolism. Immune cell trafficking, activation, differentiation, and retention are all metabolically demanding. When activated, T cells change from a quiescent state reliant on basal oxidative phosphorylation, to a highly anabolic state with increased mitochondrial production as well as increased contributions of the pentose phosphate pathway, glycolysis, and glutaminolysis to energy production. [62,63] This increased demand

for reducing equivalents may alter the glucose uptake of the VAT depot and drive the RER in the direction of CO₂ production (i.e. above 1.0). Similarly, macrophage, T-cell, and B cell polarization and production of tolerance within dendritic cells can have profound effects upon metabolism. [64-66] [67] Finally, we have previously shown in rats that SG induces reductions in jejunal expression of IL-17, IL-23, and Interferon gamma, which are correlated with weight loss and systemic insulin levels in SG animals. [68]

Thus, it is plausible that VAT-specific changes underlie the SG-related improvements in glucose handling by increasing metabolically demanding local processes, which in turn affect global metabolism. In fact, studies of caloric restriction have shown that feeding can induce adipose tissue DNL, increase RER above 1.0, and lead to innate immune modulation. [26,69]

5. Limitations:

Our study was completed in C57BL/6J mice fed normal rodent chow. Li et al., showed that SG animals in a DIO model, decreased the average RER toward 0.7. [70] These differences can be partially explained the available dietary resources in the experiment and may indicate that SG mice, when exposed to excess fat calories, adaptively increase beta oxidation. Further, in their experiment, calorimetry was performed at 7 weeks post-operatively and thus, it is possible that they missed the weight-loss independent effects that occur early in the post-surgical time course and that our finding of increased RER may become extinct as physiologic adaptation to post-surgical changes occur. The latter is in keeping with the clinical reality that the main physiologic driver of diabetes remission occurs within days of surgery and that further improvements may occur with weight loss. [1,2,5,71] Finally, given the nature of our model, we were not able to explore the weight-dependent effects of SG.

6. CONCLUSION:

SG induces immediate and durable, weight-loss independent increases in glucose utilization heralded by enhanced metabolic activity of and local immunologic remodeling of VAT. Future studies should be aimed at better understanding the interplay of host immunity and adipocyte biology to post-SG physiology.

REFERENCES:

- [1] Schauer, P.R., Bhatt, D.L., Kirwan, J.P., Wolski, K., Aminian, A., Brethauer, S.A., et al., 2017. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *Nejm* 376(7): 641–51, Doi: 10.1056/NEJMoa1600869.
- [2] Inge, T.H., Courcoulas, A.P., Jenkins, T.M., Michalsky, M.P., Helmrath, M.A., Brandt, M.L., et al., 2016. Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents. *The New England Journal of Medicine* 374(2): 113–23, Doi: 10.1056/NEJMoa1506699.
- [3] Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaiconelli, A., Leccesi, L., et al., 2012. Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. *The New England Journal of Medicine*: 120326083016000, Doi: 10.1056/NEJMoa1200111.
- [4] Yska, J.P., van Roon, E.N., de Boer, A., Leufkens, H.G.M., Wilffert, B., de Heide, L.J.M., et al., 2015. Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom. *JAMA Surgery* 150(12): 1126–33, Doi: 10.1001/jamasurg.2015.2398.
- [5] Keyvan Heshmati, M.D., David A Harris, M.D., Hassan Aliakbarian, M.D., Ali Tavakkoli, M.F., Eric Sheu, M.D.F., 2019. Comparison of early type 2 diabetes improvement after gastric bypass and sleeve gastrectomy: medication cessation at discharge predicts 1-year outcomes. *Surgery for Obesity and Related Diseases*: 1–29, Doi: 10.1016/j.soard.2019.04.004.
- [6] Segal-Lieberman, G., Segal, P., Dicker, D., 2016. Revisiting the Role of BMI in the Guidelines for Bariatric Surgery: Table 1. *Diabetes Care* 39(Supplement 2): S268–73, Doi: 10.2337/dcS15-3018.
- [7] Arble, D.M., Sandoval, D.A., Seeley, R.J., 2015. Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery. *Diabetologia* 58(2): 211–20, Doi: 10.1007/s00125-014-3433-3.
- [8] Cavin, J.-B., Bado, A., Le Gall, M., 2017. Intestinal Adaptations after Bariatric Surgery: Consequences on Glucose Homeostasis. *Trends in Endocrinology and Metabolism: TEM* 28(5): 354–64, Doi: 10.1016/j.tem.2017.01.002.
- [9] Frikke-Schmidt, H., Zamarron, B.F., O'Rourke, R.W., Sandoval, D.A., Lumeng, C.N., Seeley, R.J., 2017. Weight loss independent changes in adipose tissue macrophage and T cell populations after sleeve gastrectomy in mice. *Molecular Metabolism* 6(4): 317–26, Doi: 10.1016/j.molmet.2017.02.004.
- [10] 2013. Vertical Sleeve Gastrectomy Is Effective in Two Genetic Mouse Models of Glucagon-Like Peptide 1 Receptor De: 1–6, Doi: 10.2337/db12-1498/-/DC1.
- [11] Ding, L., Sousa, K.M., Jin, L., Dong, B., Kim, B.-W., Ramirez, R., et al., 2016. Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. *Hepatology* 64(3): 760–73, Doi: 10.1002/hep.28689.
- [12] Tian, J., Huang, S., Sun, S., Ding, L., Zhang, E., Huang, W., 2017. Bile acid signaling and bariatric surgery. *Liver Research* 1(4): 208–13, Doi: 10.1016/j.livres.2017.12.007.

- [13] Seeley, R.J., Chambers, A.P., Sandoval, D.A., 2015. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. *Cell Metabolism* 21(3): 369–78, Doi: 10.1016/j.cmet.2015.01.001.
- [14] Myronovych, A., Kirby, M., Ryan, K.K., Zhang, W., Jha, P., Setchell, K.D., et al., 2014. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. *Obesity (Silver Spring, Md.)* 22(2): 390–400, Doi: 10.1002/oby.20548.
- [15] Abu-Gazala, S., Horwitz, E., Ben-Haroush Schyr, R., Bardugo, A., Israeli, H., Hija, A., et al., 2018. Sleeve Gastrectomy Improves Glycemia Independent of Weight Loss by Restoring Hepatic Insulin Sensitivity. *Diabetes* 67(6): 1079–85, Doi: 10.2337/db17-1028.
- [16] Mithieux, G., Gautier-Stein, A., 2014. Intestinal glucose metabolism revisited. *Diabetes Research and Clinical Practice* 105(3): 295–301, Doi: 10.1016/j.diabres.2014.04.008.
- [17] Pal, A., Rhoads, D.B., Tavakkoli, A., 2015. Foregut exclusion disrupts intestinal glucose sensing and alters portal nutrient and hormonal milieu. *Diabetes* 64(6): 1941–50, Doi: 10.2337/db14-1578.
- [18] Mina, A.I., LeClair, R.A., LeClair, K.B., Cohen, D.E., Lantier, L., Banks, A.S., 2018. CalR: A Web-Based Analysis Tool for Indirect Calorimetry Experiments. *Cell Metabolism*: 1–13, Doi: 10.1016/j.cmet.2018.06.019.
- [19] Chusyd, D.E., Wang, D., Huffman, D.M., Nagy, T.R., 2016. Relationships between Rodent White Adipose Fat Pads and Human White Adipose Fat Depots. *Frontiers in Nutrition* 3(12): 1164–12, Doi: 10.3389/fnut.2016.00010.
- [20] Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., et al., 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics (Oxford, England)* 29(1): 15–21, Doi: 10.1093/bioinformatics/bts635.
- [21] Love, M.I., Huber, W., Anders, S., 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* 15(12): 1–21, Doi: 10.1186/s13059-014-0550-8.
- [22] Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., et al., 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nature Biotechnology* 28(5): 511–5, Doi: 10.1038/nbt.1621.
- [23] Cornwell, M., Vangala, M., Taing, L., Herbert, Z., Köster, J., Li, B., et al., 2018. VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. *BMC Bioinformatics* 19(1): 135–14, Doi: 10.1186/s12859-018-2139-9.
- [24] Kuleshov, M.V., Jones, M.R., Rouillard, A.D., Fernandez, N.F., Duan, Q., Wang, Z., et al., 2016. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Research* 44(W1): W90–7, Doi: 10.1093/nar/gkw377.
- [25] Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., et al., 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* 14: 128, Doi: 10.1186/1471-2105-14-128.
- [26] Bruss, M.D., Khambatta, C.F., Ruby, M.A., Aggarwal, I., Hellerstein, M.K., 2010. Calorie restriction increases fatty acid synthesis and whole body fat oxidation rates. *American Journal of Physiology. Endocrinology and Metabolism* 298(1): E108–16, Doi: 10.1152/ajpendo.00524.2009.

- [27] Leibel, R.L., Rosenbaum, M., Hirsch, J., 1995. Changes in energy expenditure resulting from altered body weight. *Nejm* 332(10): 621–8, Doi: 10.1056/NEJM199503093321001.
- [28] Rothwell, N.J., Stock, M.J., 1982. Effect of chronic food restriction on energy balance, thermogenic capacity, and brown-adipose-tissue activity in the rat. *Bioscience Reports* 2(8): 543–9.
- [29] Kalinowski, P., Paluszkiewicz, R., Wróblewski, T., Remiszewski, P., Grodzicki, M., Bartoszewicz, Z., et al., 2017. Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass-results of a randomized clinical trial. *Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery* 13(2): 181–8, Doi: 10.1016/j.soard.2016.08.025.
- [30] Du, J., Hu, C., Bai, J., Peng, M., Wang, Q., Zhao, N., et al., 2018. Intestinal Glucose Absorption Was Reduced by Vertical Sleeve Gastrectomy via Decreased Gastric Leptin Secretion. *Obesity Surgery* 317(6): 1–11, Doi: 10.1007/s11695-018-3351-4.
- [31] Belgaumkar, A.P., Vincent, R.P., Carswell, K.A., Hughes, R.D., Alaghband-Zadeh, J., Mitry, R.R., et al., 2016. Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease. *Obesity Surgery* 26(6): 1195–202, Doi: 10.1007/s11695-015-1878-1.
- [32] Yi, K.J., So, K.H., Hata, Y., Suzuki, Y., Kato, D., Watanabe, K., et al., 2015. The Regulation of Oxytocin Receptor Gene Expression during Adipogenesis. *Journal of Neuroendocrinology* 27(5): 335–42, Doi: 10.1111/jne.12268.
- [33] Reilly, S.M., Bhargava, P., Liu, S., Gangl, M.R., Gorgun, C., Nofsinger, R.R., et al., 2010. Nuclear Receptor Corepressor SMRT Regulates Mitochondrial Oxidative Metabolism and Mediates Aging-Related Metabolic Deterioration. *Cell Metabolism* 12(6): 643–53, Doi: 10.1016/j.cmet.2010.11.007.
- [34] Ghisletti, S., Huang, W., Jepsen, K., Benner, C., Hardiman, G., Rosenfeld, M.G., et al., 2009. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. *Genes & Development* 23(6): 681–93, Doi: 10.1101/gad.1773109.
- [35] Li, P., Spann, N.J., Kaikkonen, M.U., Lu, M., Oh, D.Y., Fox, J.N., et al., 2013. NCoR Repression of LXRs Restricts Macrophage Biosynthesis of Insulin-Sensitizing Omega 3 Fatty Acids. *Cell* 155(1): 200–14, Doi: 10.1016/j.cell.2013.08.054.
- [36] Guo, C., Li, Y., Gow, C.-H., Wong, M., Zha, J., Yan, C., et al., 2015. The Optimal Corepressor Function of Nuclear Receptor Corepressor (NCoR) for Peroxisome Proliferator-activated Receptor γ Requires G Protein Pathway Suppressor 2. *The Journal of Biological Chemistry* 290(6): 3666–79, Doi: 10.1074/jbc.M114.598797.
- [37] Perino, M., van Mierlo, G., Karemaker, I.D., van Genesen, S., Vermeulen, M., Marks, H., et al., 2018. MTF2 recruits Polycomb Repressive Complex 2 by helical-shape-selective DNA binding. *Nature Genetics* 50(7): 1002–10, Doi: 10.1038/s41588-018-0134-8.
- [38] Tong, Q., Dalgin, G., Xu, H., Ting, C.N., Leiden, J.M., Hotamisligil, G.S., 2000. Function of GATA transcription factors in preadipocyte-adipocyte transition. *Science (New York, NY)* 290(5489): 134–8.
- [39] Ben-Zvi, D., Meoli, L., Abidi, W.M., Nestoridi, E., Panciotti, C., Castillo, E., et al., 2018. Time-Dependent Molecular Responses Differ between Gastric Bypass and Dieting but

- Are Conserved Across Species. *Cell Metabolism*: 1–21, Doi: 10.1016/j.cmet.2018.06.004.
- [40] Ryan, K.K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., et al., 2014. FXR is a molecular target for the effects of vertical sleeve gastrectomy. *Nature* 509(7499): 183–8, Doi: 10.1038/nature13135.
 - [41] McGavigan, A.K., Garibay, D., Henseler, Z.M., Chen, J., Bettaieb, A., Haj, F.G., et al., 2015. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. *Gut: gutjnl*–2015–309871, Doi: 10.1136/gutjnl-2015-309871.
 - [42] Duncan, G.E., Howley, E.T., Johnson, B.N., 1997. Applicability of VO₂max criteria: discontinuous versus continuous protocols. *Medicine and Science in Sports and Exercise* 29(2): 273–8.
 - [43] Solinas, G., Borén, J., Dulloo, A.G., 2015. De novo lipogenesis in metabolic homeostasis: More friend than foe? *Molecular Metabolism* 4(5): 367–77, Doi: 10.1016/j.molmet.2015.03.004.
 - [44] Dereppe, H., Forton, K., Pauwen, N.Y., Faoro, V., 2019. Impact of Bariatric Surgery on Women Aerobic Exercise Capacity. *Obesity Surgery*: 1–8, Doi: 10.1007/s11695-019-03996-0.
 - [45] Saeidi, N., Meoli, L., Nestoridi, E., Gupta, N.K., Kvas, S., Kucharczyk, J., et al., 2013. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. *Science (New York, NY)* 341(6144): 406–10, Doi: 10.1126/science.1235103.
 - [46] Nakae, J., Cao, Y., Oki, M., Orba, Y., Sawa, H., Kiyonari, H., et al., 2008. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. *Diabetes* 57(3): 563–76, Doi: 10.2337/db07-0698.
 - [47] Houten, S.M., Denis, S., Argmann, C.A., Jia, Y., Ferdinandusse, S., Reddy, J.K., et al., 2012. Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. *Journal of Lipid Research* 53(7): 1296–303, Doi: 10.1194/jlr.M024463.
 - [48] Fenouille, N., Bassil, C.F., Ben-Sahra, I., Benajiba, L., Alexe, G., Ramos, A., et al., 2017. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. *Nature Publishing Group* 23(3): 301–13, Doi: 10.1038/nm.4283.
 - [49] Witte, N., Muenzner, M., Rietscher, J., Knauer, M., Heidenreich, S., Nuotio-Antar, A.M., et al., 2015. The Glucose Sensor ChREBP Links De Novo Lipogenesis to PPAR γ Activity and Adipocyte Differentiation. *Endocrinology* 156(11): 4008–19, Doi: 10.1210/EN.2015-1209.
 - [50] Li, P., Fan, W., Xu, J., Lu, M., Yamamoto, H., Auwerx, J., et al., 2011. Adipocyte NCoR knockout decreases PPAR γ phosphorylation and enhances PPAR γ activity and insulin sensitivity. *Cell* 147(4): 815–26, Doi: 10.1016/j.cell.2011.09.050.
 - [51] Zhuang, Q., Li, W., Benda, C., Huang, Z., Ahmed, T., Liu, P., et al., 2018. NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming. *Nature Cell Biology* 20(4): 400–12, Doi: 10.1038/s41556-018-0047-x.
 - [52] Goodson, M.L., Young, B.M., Snyder, C.A., Schroeder, A.C., Privalsky, M.L., 2014. Alteration of NCoR corepressor splicing in mice causes increased body weight and

- hepatosteatosis without glucose intolerance. *Molecular and Cellular Biology* 34(22): 4104–14, Doi: 10.1128/MCB.00554-14.
- [53] Choudhary, A.K., Dey, C.S., 2017. Nuclear co-repressor (NCoR) is required to maintain insulin sensitivity in C2 C12 myotubes. *Cell Biology International* 41(2): 204–12, Doi: 10.1002/cbin.10711.
- [54] Ayoub, E., Wilson, M.P., McGrath, K.E., Li, A.J., Frisch, B.J., Palis, J., et al., 2018. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription. *Nature Communications* 9(1): 4239, Doi: 10.1038/s41467-018-06208-y.
- [55] Zhao, G.-N., Jiang, D.-S., Li, H., 2015. Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. *Biochimica Et Biophysica Acta* 1852(2): 365–78, Doi: 10.1016/j.bbadis.2014.04.030.
- [56] Shaw, L.A., Bélanger, S., Omilusik, K.D., Cho, S., Scott-Browne, J.P., Nance, J.P., et al., 2016. Id2 reinforces TH1 differentiation and inhibits E2A to repress TFH differentiation. *Nature Immunology* 17(7): 834–43, Doi: 10.1038/ni.3461.
- [57] Rogers, J.H., Owens, K.S., Kurkewich, J., Klopfenstein, N., Iyer, S.R., Simon, M.C., et al., 2016. E2A Antagonizes PU.1 Activity through Inhibition of DNA Binding. *BioMed Research International* 2016(8): 3983686–11, Doi: 10.1155/2016/3983686.
- [58] Li, F., Wu, R., Cui, X., Zha, L., Yu, L., Shi, H., et al., 2016. Histone Deacetylase 1 (HDAC1) Negatively Regulates Thermogenic Program in Brown Adipocytes via Coordinated Regulation of Histone H3 Lysine 27 (H3K27) Deacetylation and Methylation. *The Journal of Biological Chemistry* 291(9): 4523–36, Doi: 10.1074/jbc.M115.677930.
- [59] Lee, S.C.W., Miller, S., Hyland, C., Kauppi, M., Lebois, M., Di Rago, L., et al., 2015. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis. *Blood* 126(2): 167–75, Doi: 10.1182/blood-2014-12-615898.
- [60] Dufort, F.J., Gumina, M.R., Ta, N.L., Tao, Y., Heyse, S.A., Scott, D.A., et al., 2014. Glucose-dependent de Novo Lipogenesis in B Lymphocytes. *The Journal of Biological Chemistry* 289(10): 7011–24, Doi: 10.1074/jbc.M114.551051.
- [61] Yilmaz, M., Claiborn, K.C., Hotamisligil, G.S., 2016. De Novo Lipogenesis Products and Endogenous Lipokines. *Diabetes* 65(7): 1800–7, Doi: 10.2337/db16-0251.
- [62] Desdín-Micó, G., Soto-Heredero, G., Mittelbrunn, M., 2018. Mitochondrial activity in T cells. *Mitochondrion* 41: 51–7, Doi: 10.1016/j.mito.2017.10.006.
- [63] Baixauli, F., Acín-Pérez, R., Villarroya-Beltrí, C., Mazzeo, C., Nuñez-Andrade, N., Gabandé-Rodríguez, E., et al., 2015. Mitochondrial Respiration Controls Lysosomal Function during Inflammatory T Cell Responses. *Cell Metabolism* 22(3): 485–98, Doi: 10.1016/j.cmet.2015.07.020.
- [64] McLaughlin, T., Ackerman, S.E., Shen, L., Engleman, E., 2017. Role of innate and adaptive immunity in obesity-associated metabolic disease. *The Journal of Clinical Investigation* 127(1): 5–13, Doi: 10.1172/JCI88876.
- [65] Lee, Y.S., Wollam, J., Olefsky, J.M., 2018. An Integrated View of Immunometabolism: 1–19, Doi: 10.1016/j.cell.2017.12.025.
- [66] Nishimura, S., Manabe, I., Takaki, S., Nagasaki, M., Otsu, M., Yamashita, H., et al., 2013. Adipose Natural Regulatory B Cells Negatively Control Adipose Tissue Inflammation. *Cell Metabolism* 18(5): 759–66, Doi: 10.1016/j.cmet.2013.09.017.

- [67] Malinarich, F., Duan, K., Hamid, R.A., Bijin, A., Lin, W.X., Poidinger, M., et al., 2015. High Mitochondrial Respiration and Glycolytic Capacity Represent a Metabolic Phenotype of Human Tolerogenic Dendritic Cells. *The Journal of Immunology* 194(11): 5174–86, Doi: 10.4049/jimmunol.1303316.
- [68] Subramaniam, R., Aliakbarian, H., Bhutta, H.Y., Harris, D.A., Tavakkoli, A., Sheu, E.G., 2019. Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Attenuate Pro-inflammatory Small Intestinal Cytokine Signatures. *Obesity Surgery*: 1–9, Doi: 10.1007/s11695-019-04059-0.
- [69] Wu, Z., Isik, M., Moroz, N., Steinbaugh, M.J., Zhang, P., Blackwell, T.K., 2019. Dietary Restriction Extends Lifespan through Metabolic Regulation of Innate Immunity. *Cell Metabolism*: 1–23, Doi: 10.1016/j.cmet.2019.02.013.
- [70] Li, P., Rao, Z., Laing, B., Bunner, W.P., Landry, T., Prete, A., et al., 2019. Vertical sleeve gastrectomy improves liver and hypothalamic functions in obese mice. *The Journal of Endocrinology* 241(2): 135–47, Doi: 10.1530/JOE-18-0658.
- [71] Schauer, P.R., Bhatt, D.L., Kirwan, J.P., Wolski, K., Brethauer, S.A., Navaneethan, S.D., et al., 2014. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. *The New England Journal of Medicine* 370(21): 2002–13, Doi: 10.1056/NEJMoa1401329.

FIGURES

Figure 1. Experimental design.

Figure 2: Post-operative weight (A), daily food intake (B), and body composition (C) between Sham (n=4) and SG (n=4) mice. A and B, n = 4,4. For C, n=5,5 and data is representative of 3 biologic replicates. Comparisons by Students' t-tests. *p<0.05

Figure 3: (A,B) Oral glucose tolerance testing at 2 and 4 weeks (A; SG n=9, Sham n=10, B; n=4,4). (C) Insulin tolerance testing at 2 weeks (SG n=6, Sham n=6). (D) Total GLP1 levels at 15 minutes following glucose challenge (SG n=4 and Sham n=5). Comparisons made using t-tests. *p<0.05, **p<0.01, ***P<0.001. ++ One sham and two SG animals had to be rescued from hypoglycemia at this time point.

Figure 4: SG mice have continuously elevated RERs (average 0.9 to 1.05) indicating preferential glucose utilization during both feeding and fasting. Sham mice demonstrate normal RER excursions, reflective of mixed lipid/glucose utilization (A). SG mice have higher average RER (B) and lower EE over a 24 hour period, while feeding, and while fasting (C); Combination of 3 biologic replicates. SG n=15 and sham n=14; t-test, *p<0.05, **p<0.01, ***p<0.001

Figure 5: (A) Representative PET/CT images from Sham (left) and SG (right) animals 1 hour after oral 18-FDG administration during post operative week 2. Red denotes high and green, low 18-FDG avidity. (B) Time activity curves were generated (n=2,2). (C) 18-FDG avidity across all fat depots as measured by well counter (C: SG n=4, sham n=5). *p<0.05

Table 1. Top changes in relative gene expression in the visceral fat of SG compared to Sham animals. Base >100, Fold change >1.0, and p<0.05. n=5,5

<u>UPREGULATION</u>		<u>DOWN REGULATION</u>	
Ehhadh	Ldb3	Ehd3	Nnat
Cxcl13	Cish	Oxtr	Mroh2a
Igj	Ccl8	Lep	Sfrp5
		Atp6v0d2	

Table 2. Upregulated specific pathway changes identified in SG animals through functional enrichment analysis using WikiPathways 2019 Mouse. n=5,5

<u>PATHWAY</u>	<u>P-VALUE</u>	<u>COMBINED SCORE</u>
Chemokine Signaling	0.023	76.7
TYROBP Causal Network	0.024	62.0
Microglia Pathogen Phagocytosis	0.010	56.0
Macrophage Markers	0.036	45.6
IL-2 Signaling	0.001	45.1
IL-3 Signaling	0.001	29.2
IL-5 Signaling	0.036	15.7

Figure 6: ChEA2016 transcription pathway analysis showing the most up regulated (left) and down regulated (right) transcription pathways. Data is organized as clustergrams with a red bar denoting a gene contributing to the pathway expression. Only pathways with an adjusted $p < 0.05$ are included. Pathway titles are followed by the combined score. Base > 50, log change > 0.5, $p < 0.05$